Epigral Q1 FY27 PAT rises 25% to ₹99 crore

Key takeaway from the June quarter

Epigral Limited reported a 25% year-on-year rise in profit after tax (PAT) to ₹99 crore for the quarter ended June 30, 2026. Revenue from operations grew 15% year-on-year to ₹709 crore during the same period. The company attributed the performance to a 5% increase in sales volume and improved realizations. It also reported maintaining an EBITDA margin of 25% for the quarter.

Q1 FY27 numbers: profit, revenue, and margins

For Q1 FY27, Epigral’s EBITDA was reported at ₹179 crore, up 10% from ₹163 crore in Q1 FY26. The company reported a PAT margin of 14% and an EBITDA margin of 25%. It also reported ROCE at 16% as on June 30, 2026, compared with 24% in the year-ago period, a decline of 8 percentage points. Net Debt/EBITDA stood at 0.8x as on June 30, 2026.

Why the YoY profit comparison appears different in disclosures

Alongside the 25% YoY PAT growth figure (₹99 crore versus ₹79 crore), the data also shows another year-on-year comparison against a higher base. Epigral reported a standalone net profit of ₹99.18 crore for the quarter ended June 30, 2026, compared with ₹160.41 crore in the corresponding period of FY25. Consolidated net profit was ₹99.74 crore versus ₹160.69 crore in Q1 FY25.

The company’s earlier Q1 FY26 disclosure cited PAT of ₹160 crore that included a one-time credit of ₹81 crore due to a shift to a new tax regime, with adjusted PAT stated at ₹79 crore. This makes the quarter-on-quarter and year-on-year interpretation sensitive to whether the comparison uses reported PAT or adjusted PAT.

EBITDA trend and margin movement

For the June 2026 quarter, EBITDA was also presented as ₹1.8 billion, which is approximately ₹180 crore, versus ₹1.6 billion or about ₹160 crore in the year-ago period. The EBITDA margin for the quarter was stated at 25.39%, compared with 27% year-on-year. In the same results set, the company highlighted that it maintained an EBITDA margin of 25% despite changes in operating conditions.

Balance sheet snapshot: leverage and return metrics

Epigral reported Net Debt/EBITDA of 0.8x as on June 30, 2026. In the comparable historical disclosures, Net Debt/EBITDA was stated at 0.6x as on June 30, 2025 and 1.59x as on June 30, 2024. ROCE was reported at 16% as on June 30, 2026, compared with 24% as on June 30, 2025.

Board clears ₹600 crore strategic expansion

The board approved a strategic expansion with an estimated capex of ₹600 crore. The investment covers two projects: an Epoxy Resin and Formulations plant and a Multi-Purpose Plant (MPP). Epigral said the epoxy resin facility is planned with a production capacity of 1,25,000 TPA. The company described this as forward integration into advanced materials, serving end-use sectors such as renewable energy, automotive, electronics, and infrastructure.

Multi-Purpose Plant to target pharma and agrochem intermediates

The Multi-Purpose Plant (MPP) is designed to manufacture downstream products of the Epichlorohydrin (ECH) and Chlorotoluenes value chains. The company positioned the MPP as a response to domestic demand for pharmaceutical and agrochemical intermediates. Both the epoxy resin plant and the MPP are expected to be commissioned in H2 FY28.

Pilot plants planned by Q2 FY27

To validate product quality and optimise processes, Epigral is establishing pilot plant facilities for both units. The pilot plants are targeted for operation by Q2 FY27. The company linked the pilot setup to product validation and process optimisation ahead of full-scale commissioning.

CPVC and ECH expansions: capacity additions and timelines

Epigral also stated that capex for enhancing CPVC Resin, ECH, and Wind Solar Hybrid Power Plant capacities is progressing as per schedule and is expected to be commissioned within timeline and budget. The CPVC resin expansion will add 75,000 TPA, taking total CPVC capacity to 1,50,000 TPA. The ECH expansion will add 50,000 TPA, taking total ECH capacity to 1,00,000 TPA. Both expansions are expected to be commissioned in Q2 FY27.

Where investors can track the filings and next steps

The company said the un-audited results are available on its website under the Investor Relations section. It also disclosed that a conference call to discuss Q1 FY27 results is scheduled on Monday, July 27, 2026 at 5:00 PM (IST). The call invite listed participation from chairman and managing director Maulik Patel, executive director Kaushal Soparkar, CFO Rakesh Agrawal, and investor relations and strategy head Milind Kotecha.

Summary table: financials and project milestones

Market impact and why this update matters

For investors tracking specialty and derivative chemical plays, the Q1 FY27 update combines near-term operating performance with a clear capacity roadmap. The quarter’s reported revenue growth and 25% EBITDA margin indicate stable operating profitability in the company’s own presentation, while the comparison against FY25 profit underscores the effect of one-off tax items on reported year-on-year swings. The leverage metric of Net Debt/EBITDA at 0.8x provides a datapoint for how the company is positioned as it enters a new capex cycle.

Conclusion

Epigral’s June-quarter update reported ₹709 crore revenue and ₹99 crore PAT, with EBITDA margin held around 25%. The board-approved ₹600 crore expansion and the scheduled commissioning timelines across Q2 FY27 and H2 FY28 put the next set of operating milestones in focus, with management expected to address details on the July 27, 2026 conference call.